Daewoong Pharmaceutical presents Phase 1 Plodicitinib clinical data at ACR

Résumé détaillé
South Korean drugmaker Daewoong Pharmaceutical presented Phase 1 clinical trial data for its autoimmune disease candidate Plodicitinib during the ACR Convergence 2026 conference on 17 November 2026.
SEOUL, South Korea and ORLANDO, Fla., Nov. 17, 2026 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Changjae Lee) announced that it presented data from the Phase 1 clinical trial of its new drug candidate for autoimmune diseases, 'Plodicitinib(DWP212525)', at the 'American College of Rheumatology (ACR) Convergence 2026' held on November 9 (local time) in Orlando, Florida.
Plodicitinib is an oral new drug candidate currently being developed by Daewoong Pharmaceutical as a treatment for autoimmune and inflammatory diseases. By selectively inhibiting JAK3—which regulates the activity and function of immune cells—as well as ITK and BTK, which are involved in the activation of T cells and B cells (key immune cells), it modulates the excessively activated immune response in patients with autoimmune diseases to an appropriate level.
Unlike many existing treatments for inflammatory and autoimmune diseases, which are limited to inhibiting T cells or B cells, Plodicitinib has a distinct mechanism of action: it simultaneously targets JAK3, ITK, and BTK, enabling it to broadly modulate immune responses in which T cells and B cells are involved in a complex manner. Based on this, it is expected to have potential applications in various autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome.
At this conference, results from the first-in-human Phase 1 single-ascending dose (SAD) clinical trial of Plodicitinib, conducted in 44 healthy adults, were presented. Analysis revealed that the maximum target occupancy for both BTK and ITK—the primary targets—exceeded 90%. Target occupancy is an indicator of the extent to which a drug binds to its target protein; these results provide initial pharmacodynamic evidence of Plodicitinib target engagement.
Pharmacokinetic(PK) evaluations showed that drug exposure in the body increased with higher doses.
Following the completion of the SAD study, Daewoong Pharmaceutical is currently…
Pr…
Début de l'article, extrait de Vietnam Investment Review. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (vir.com.vn)




